A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

PHASE2WithdrawnINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Chronic Myeloid Leukemia, Blast CrisisAcute Myeloid Leukemia
Interventions
DRUG

Imatinib Mesylate

Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15

DRUG

CLAG

"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"

Trial Locations (1)

45267

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Cincinnati

OTHER